Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis
Completed
Amgen
Phase 2
2007-03-05
This study is to look at the preliminary efficacy and safety of 2 dose regimens of apremilast
(20 mg twice a day and 40 mg once a day) versus placebo in patients with active psoriatic
arthritis.
Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis
Completed
Celgene Corporation
Phase 2
2007-03-05
This study is to look at the preliminary efficacy and safety of 2 dose regimens of apremilast
(20 mg twice a day and 40 mg once a day) versus placebo in patients with active psoriatic
arthritis.
Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis
Completed
Amgen
Phase 2
2005-01-01
Open label study for patients with severe plaque type psoriasis. This study is looking to
evaluate the pharmacodynamic effect of CC10004 when taken for 29 days in reducing the
epidermal thickness in subjects with severe placque type psoriasis.
Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis
Completed
Celgene Corporation
Phase 2
2005-01-01
Open label study for patients with severe plaque type psoriasis. This study is looking to
evaluate the pharmacodynamic effect of CC10004 when taken for 29 days in reducing the
epidermal thickness in subjects with severe placque type psoriasis.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
